ADXS:NSD-Advaxis, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.53

Change

-0.01 (-2.21)%

Market Cap

USD 0.03B

Volume

0.78M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) which is phase II clinical trial for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product developed using whole-exome sequencing of a patient's tumor to identify neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+6.03 (+2.60%)

USD61.69B 52.76 43.54
REGN Regeneron Pharmaceuticals, Inc

+15.29 (+3.23%)

USD52.04B 25.62 18.92
SGEN Seattle Genetics, Inc

+0.09 (+0.08%)

USD18.82B N/A -91.93
ALXN Alexion Pharmaceuticals, Inc

+2.53 (+2.90%)

USD18.60B 7.85 7.48
INCY Incyte Corporation

+1.06 (+1.47%)

USD14.95B 33.64 27.08
BMRN BioMarin Pharmaceutical Inc

+2.01 (+2.44%)

USD14.84B N/A 31,783.95
GMAB Genmab A/S

+0.71 (+3.47%)

USD12.83B N/A N/A
BNTX BioNTech SE

-3.60 (-5.81%)

USD12.47B N/A N/A
ALNY Alnylam Pharmaceuticals, Inc

+0.02 (+0.02%)

USD11.78B N/A -11.75
GLPG Galapagos NV

+5.54 (+2.91%)

USD11.64B 72.40 N/A

ETFs Containing ADXS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.23% 31% F 30% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.23% 30% F 30% F
Trailing 12 Months  
Capital Gain -91.86% 2% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -91.86% 2% F 2% F
Trailing 5 Years  
Capital Gain -99.77% 4% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -99.77% 3% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -59.66% 3% F 1% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.66% 3% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 34.99% 64% D 37% F
Risk Adjusted Return -170.54% 4% F 1% F
Market Capitalization 0.03B 20% F 24% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 0.81 87% B+ 69% D+
Price / Cash Flow Ratio -0.93 23% F 65% D
EV/EBITDA -0.19 25% F 62% D-
Management Effectiveness  
Return on Equity -94.34% 34% F 13% F
Return on Invested Capital -50.25% 57% F 18% F
Return on Assets -41.98% 28% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.70 82% B- 81% B-
Short Percent 5.94% 57% F 40% F
Beta 4.08 1% F 2% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.